Clinical trials: Patients With Bipolar Disorders
Bipolar 1 Disorder
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.
- Trial name
- NCT01674010
- Testing
- ELND005, Lamotrigine, Valproic acid
- Where
- 82 sites in United States, Bulgaria and 7 more
- Volunteers
- 309 people
- Sponsor
- OPKO Health, Inc.
Bipolar Depression
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868959
- Testing
- lurasidone
- Where
- 151 sites in United States, Canada and 13 more
- Volunteers
- 817 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder
A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.
- Trial name
- NCT00282464
- Testing
- Geodon (Ziprasidone)
- Where
- 43 sites in United States
- Volunteers
- 392 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder I or II
Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine
A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.
- Trial name
- NCT00259272
- Testing
- olanzapine
- Where
- 16 sites in France
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
High Deductible Health Plans and Bipolar Disorder
Using eleven years (2004-2014) of claims data from the largest US commercial health insurer, the investigators will assess the impact of switching into high-deductible health plans (HDHPs) on outcomes for patients with bipolar…
- Trial name
- NCT02560701
- Testing
- Patient Interview
- Volunteers
- 350,823 people, healthy volunteers welcome
- Sponsor
- Harvard Pilgrim Health Care
Bipolar Disorder, Schizophrenia
Non Interventional Study In Bipolar Disorder And Schizophrenia With Zeldox
Investigation of the impact of Zeldox on metabolic parametres in patients with bipolar disorder or with schizophrenia and impact of the treatment for the quality of life
- Trial name
- NCT00538629
- Testing
- no intervention
- Volunteers
- 471 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Depression
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
- Trial name
- NCT01986101
- Testing
- SM-13496
- Where
- 8 sites in Japan, Lithuania and 6 more
- Volunteers
- 525 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Bipolar Disorder
Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder
The purpose of this study is to determine whether treating sleep difficulties in patients with bipolar disorder also improves their mood stability.
- Trial name
- Ram-TIME (NCT00552760)
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Lehigh Valley Hospital
Bipolar Disorder
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania.
- Trial name
- NCT00488618
- Testing
- Cariprazine (RGH-188)
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Forest Laboratories
Bipolar I Disorder
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
To investigate the safety and efficacy of long-term administration of aripiprazole by performing extended administration of the treatment administered in the preceding multicenter, double-blind, placebo-controlled, parallel…
- Trial name
- NCT00606177
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 99 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
Cost- Effectiveness and Quality of Life Assessment in Mood Disorder
To evaluate the effectiveness of three systematic interventions for Bipolar Disorder (BD) mixed episodes using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these…
- Trial name
- NCT02870283
- Testing
- Lithium, Valproic Acid, Carbamazepine
- Volunteers
- 107 people
- Sponsor
- Federal University of Rio Grande do Sul
Bipolar Disorder, Mania
Safety and Efficacy of Cariprazine for Mania
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.
- Trial name
- NCT01058096
- Testing
- Cariprazine
- Where
- 28 sites in United States, India
- Volunteers
- 323 people
- Sponsor
- Forest Laboratories
Bipolar Disorder, Obesity
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms.
- Trial name
- NCT03158805
- Testing
- LIRAGLUTIDE
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Lindner Center of HOPE
Cancer, Severe Major Depression
Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.
- Conditions
- Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder
- Trial name
- NCT03360695
- Testing
- Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Massachusetts General Hospital
HIV Disease, Bipolar Disorder
Texting to Improve Adherence in HIV+ With Bipolar Disorder
Adherence to combination antiretroviral therapy (ART) is critical for successful HIV viral suppression. Nonadherence to ART poses several potentially serious health consequences, including higher viral loads, faster progression…
- Trial name
- iTAB (NCT02090634)
- Testing
- Psychoeducation, individualized Texting for Adherence Building (iTAB)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Diego
Depression
Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
This is a postmarket medical device study. The objective of this study is to compare the safety and effectiveness of Vagus Nerve Stimulation (VNS) Therapy administered at different amounts of electrical charge for the treatment…
- Trial name
- NCT00305565
- Testing
- VNS Therapy
- Where
- 26 sites in United States
- Volunteers
- 331 people
- Sponsor
- Cyberonics, Inc.
Bipolar Disorder, Anxiety
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
The primary objective is to test the hypothesis that Quetiapine XR (Extended Release) monotherapy and adjunctive therapy is effective in the acute treatment of bipolar depression and comorbid generalized anxiety disorder in…
- Conditions
- Bipolar Disorder, Anxiety, Anxiety Disorders, Substance Use Disorders
- Trial name
- NCT00671853
- Testing
- Quetiapine XR
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University Hospitals Cleveland Medical Center
Bipolar Disorder
A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
In period I, the treatment effect of FK949E was compared with that of placebo in a blind manner in bipolar disorder patients with major depressive episodes. In period II, the long-term safety and efficacy of FK949E was evaluated.
- Trial name
- NCT01725308
- Testing
- FK949E
- Where
- 98 sites in Japan
- Volunteers
- 431 people
- Sponsor
- Astellas Pharma Inc
Bipolar Disorder
One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of Ziprasidone HCl on the distribution of metabolic syndrome (MS) risk factors in a population of Bipolar patients presenting with glucose intolerance, dyslipidemia and/or…
- Trial name
- NCT01113541
- Testing
- Ziprasidone HCL (oral)
- Where
- 10 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.